For two decades, Shaquille O’Neal was the most physically dominant athlete on the planet. Seven feet one inch, well over 300 pounds, four NBA championships, a Hall of Fame career built on overpowering everyone in his path.

And every night, his own body was quietly working against him.

The snoring. The daytime exhaustion. The inability to focus. For years, Shaq wrote it all off as the price of being enormous. It took a sleep study, a diagnosis, and — more than a decade later — a prescription peptide-based medication for him to confront what was actually happening. In June 2026, he went public about using Zepbound (tirzepatide) to treat obstructive sleep apnea.

His story is worth your attention — not because a celebrity took a weight-loss drug, but because of what it says about how even the most successful people avoid dealing with their health until something forces the issue.

Why Shaq’s story matters

Shaq is not a cautionary tale of neglect. He was a professional athlete with access to the best trainers, doctors, and recovery resources money can buy. He still spent years normalizing symptoms that turned out to be a treatable medical condition.

According to Eli Lilly’s announcement, it was only after retiring from the NBA in 2011 that O’Neal took part in an overnight sleep study and learned that the fatigue, loud snoring, and trouble focusing he had lived with were symptoms of obstructive sleep apnea (OSA).

“For a long time, I was tired during the day, not sleeping well at night, and I just thought that’s how it was for someone my size.” — Shaquille O’Neal, via Eli Lilly

That sentence is the whole story in miniature: I just thought that’s how it was. Most people with sleep apnea think the same thing. The American Academy of Sleep Medicine estimates tens of millions of American adults have OSA, and most cases go undiagnosed.

What Shaq actually said about Zepbound

In a June 2026 GQ interview and an accompanying Lilly campaign called “Watch This,” O’Neal described being prescribed Zepbound by his doctor as part of his OSA treatment.

“I chose to share my experience because OSA is a serious but often overlooked condition… I can remember, especially when I stopped playing, the snoring, the daytime tiredness, a lot of fatigue, and being unable to focus. So this is very personal to me.”

He told Lilly the medication “helped make a real difference for me in my OSA treatment journey; I even lost some weight.” Alongside the prescription, he described real lifestyle changes: regular exercise on an elliptical and a bike, more walking, and a reduced-calorie diet.

One thing to be clear-eyed about: this is a paid national ad campaign. Shaq is a spokesperson for Zepbound, and Lilly has a commercial interest in his story being told. That doesn’t make his experience false — his OSA diagnosis predates the campaign by 15 years — but you should read every celebrity health story with the sponsorship in plain view. We’re flagging it here so you can weigh it yourself.

What Zepbound actually is

Zepbound is the brand name for tirzepatide, a synthetic peptide medication made by Eli Lilly. It is an FDA-approved prescription drug — not a supplement, and not one of the gray-market “research peptides” sold online.

In plain terms, tirzepatide is a single molecule that activates two of your gut’s natural hormone signals at once:

  • GLP-1 (glucagon-like peptide-1) — released after you eat; it signals fullness to your brain, slows stomach emptying, and helps regulate insulin.
  • GIP (glucose-dependent insulinotropic polypeptide) — a second incretin hormone that works alongside GLP-1 on appetite and how your body handles glucose and fat.

Because it hits both receptors, tirzepatide is often called a “dual agonist.” If GLP-1 drugs are new territory for you, our explainer on what GLP-1 peptides are and what the research shows covers the trial data in more depth.

The regulatory history matters here:

  • November 2023: the FDA approved Zepbound for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
  • December 2024: the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA. The approval was based on the SURMOUNT-OSA trials, where participants on tirzepatide had significantly fewer breathing interruptions during sleep than those on placebo.

That second approval is what makes Shaq’s case different from the usual celebrity weight-loss story. His prescription targets a diagnosed sleep disorder, not a number on a scale.

Why sleep apnea is a bigger deal than snoring

Obstructive sleep apnea means your airway repeatedly collapses or narrows during sleep. Each event can drop your blood oxygen and jolt your brain partially awake — sometimes dozens of times per hour, all night, without you remembering any of it.

The downstream effects read like a list of everything longevity-focused people care about:

  • Cardiovascular strain. OSA is associated with high blood pressure, heart rhythm problems, and elevated cardiovascular risk.
  • Daytime cognitive cost. Fragmented sleep degrades attention, memory, and reaction time — the same deficits we covered in our piece on how long it takes to recover from sleep debt.
  • Metabolic disruption. Poor sleep worsens insulin sensitivity and appetite regulation, which can drive further weight gain — which in turn worsens OSA. It’s a loop.

Excess weight is one of the biggest risk factors, because tissue around the airway makes collapse more likely. That’s the logic behind the Zepbound approval: meaningful weight reduction can directly reduce the severity of airway obstruction.

The real life change: it wasn’t just weight

Read Shaq’s comments closely and the weight loss is almost a footnote — “I even lost some weight.” What he emphasizes is sleeping through the night, having energy during the day, and being able to focus.

That’s the part of this story worth taking seriously. The “major life change” wasn’t a smaller jersey size. It was:

  • Getting tested. A sleep study turned vague, normalized symptoms into a concrete diagnosis.
  • Taking a diagnosis seriously — even 15 years later, even as a multimillionaire with no boss telling him to.
  • Combining medication with behavior. Diet changes, cardio, daily walking. Zepbound’s own label requires pairing it with reduced calories and increased activity — the drug is a tool inside a lifestyle, not a replacement for one.
  • Talking about it publicly, in a demographic — large, older, successful men — that statistically avoids doctors.

For the longevity-minded reader, energy, sleep quality, and metabolic health compound over decades. They’re the same reasons we advocate boring fundamentals like zone 2 cardio for mitochondrial health.

This is not the same as buying peptides online

Here’s where the biohacker audience needs the sharpest distinction.

Shaq’s tirzepatide came through a physician’s diagnosis, a prescription, and the regulated pharmaceutical supply chain. The vials of “tirzepatide” sold by online peptide vendors, unlicensed sellers, and some compounding operations are a different universe.

The FDA has publicly warned about unapproved GLP-1 products, citing more than a thousand adverse event reports tied to compounded semaglutide and tirzepatide — including hospitalizations from dosing errors, plus counterfeit products with unknown ingredients found in the supply chain. Unapproved versions never go through FDA review for safety, effectiveness, or quality.

A peptide labeled “for research use only” is not a budget version of Zepbound. It is an unverified chemical with no guarantee of identity, purity, sterility, or concentration. With injectable drugs that affect blood sugar and gastric function, that uncertainty is a genuine health risk, not a technicality.

One useful tell: established research-peptide suppliers like Best Days don’t sell GLP-1 compounds at all. A vendor offering “research tirzepatide” to the public is selling exactly the category of product the FDA is warning about.

Safety, supervision, and what we’re not saying

To be direct about what this article is and isn’t:

  • We are not suggesting you should take Zepbound or any GLP-1. That’s a decision for you and a licensed clinician who knows your history.
  • These medications have real side effects. Gastrointestinal effects are common; pancreatitis, gallbladder problems, and other serious events are documented. Tirzepatide isn’t appropriate for everyone.
  • No drug is a “cure” for sleep apnea or obesity. Trial results are averages; individual results vary, and stopping GLP-1 medications typically leads to weight regain without sustained lifestyle change.
  • If you suspect sleep apnea — loud snoring, gasping at night, unrefreshing sleep, daytime fatigue — the move isn’t a drug. It’s a conversation with a doctor and, likely, a sleep study. Diagnosis first. Always.

Key lessons for biohackers

  1. Symptoms you’ve normalized are still data. Shaq spent years assuming exhaustion was just part of being big. “That’s just how I am” is the most common way real conditions hide.
  2. Testing beats guessing. One sleep study did more for Shaq than a decade of self-assessment. Labs, sleep studies, and actual diagnoses are the foundation real optimization is built on.
  3. Regulated beats gray-market. The same molecule can be a rigorously manufactured prescription drug or an unverified vial from an anonymous vendor. The molecule isn’t the only thing that matters — the supply chain is part of the safety profile.
  4. Drugs amplify habits; they don’t replace them. Even with a pharmaceutical assist, Shaq changed his diet and trains daily. Every GLP-1 approval explicitly assumes diet and exercise alongside it.
  5. Read the sponsorship. Shaq’s story is real and it’s an ad. Holding both facts at once is exactly the media literacy this space requires.

The bottom line

The most interesting thing about Shaq’s Zepbound story isn’t the peptide. It’s that one of the most physically gifted humans alive needed a diagnosis, medical guidance, and consistent daily habits to fix something as fundamental as sleep.

Real biohacking starts there — testing, diagnosis, professional supervision, consistency — not with a vial from an unregulated website. If a four-time NBA champion can admit he needed help and go through the proper channels to get it, the rest of us can book the sleep study.

Readers who want to explore the peptide research literature more broadly can browse Best Days, a catalog of research-grade peptides intended for laboratory use — such as MOTS-c, a mitochondrial-derived peptide studied in metabolic-health research, and the Longevity Stack.

To be consistent with everything above: Best Days does not sell tirzepatide, semaglutide, or any GLP-1 compound — and you should be skeptical of any research-peptide vendor that does. Research peptides are explicitly not for human consumption and are not a substitute for prescription medication or medical care. For clinical access to FDA-approved GLP-1 medications, talk to your physician or a licensed telehealth provider.

This article is for educational purposes only and is not medical advice. It does not endorse or recommend any medication. Zepbound is a prescription medicine with significant potential side effects; talk to a licensed healthcare professional about any concerns regarding sleep apnea, weight, or whether any treatment is appropriate for you. Shaquille O’Neal’s campaign with Eli Lilly is a paid commercial partnership. Biohack Library has a commercial relationship with Best Days and may earn revenue from purchases made through the links above.

Sources